NYSE
$0.1960▲ 1.71%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $9.0MShares out 45.9M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
7- 4d agoAfter-hours26.10.21 05:15DEF 14AOther#●●●#●●●#●●●
Theriva Biologics, Inc.
Theriva Biologics will hold a special meeting of stockholders on November 18, 2026, to vote on increasing the authorized common stock from 450 million to 500 million shares. The company is also seeking to ratify the issuance of up to 16,184,560 shares of common stock upon the exercise of warrants from a private placement that closed on October 17, 2025. These measures are intended to provide the company with sufficient flexibility for future equity financings and strategic transactions.…more
$0.1960+1.71%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.9After-hours26.10.10 05:45PRE 14AOther
Theriva Biologics, Inc.
Theriva Biologics will hold a special meeting of stockholders in November 2026 to vote on increasing the authorized common stock from 450 million to 500 million shares. The company is also seeking to ratify the issuance of up to 16,184,560 shares of common stock upon the exercise of warrants issued in a private placement that closed on October 17, 2025. These measures are intended to provide the company with greater flexibility for future equity financing and strategic transactions.…more
$0.1960+1.71%vs prev closeView filingShare - 8.24After-hours26.08.25 06:00S-8Offering
Theriva Biologics, Inc.
Theriva Biologics has registered an additional 2,000,000 shares of common stock pursuant to Amendment No. 4 to the 2020 Stock Incentive Plan, which was approved at the 2026 Annual Meeting of Stockholders on August 3, 2026. This registration increases the total number of shares available for issuance under the plan to 6,500,000 shares.…more
$0.1960+1.71%vs prev closeView filingShare
6 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.1Overnight26.10.01 11:34#●●●#●●●
Theriva Biologics Announces Publication of VIRAGE Phase 2b Trial Results in Nature Medicine…more
Theriva Biologics' Phase 2b clinical trial results for its pancreatic cancer candidate VCN-01 have been published in Nature Medicine, validating the study's findings. The company is currently conducting the VIRAGE2 trial to evaluate optimized dosing regimens for future Phase 3 development.…more
$0.1960+1.71%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 9.30Pre-market26.09.30 21:03
●●●●●●●● ●●●●● ●●●●●●
Theriva Biologics announced the publication of its Phase 2b clinical trial results for VCN-01 in metastatic pancreatic cancer in the journal Nature Medicine. As the announcement focuses on academic publication without immediate commercial or regulatory milestones, the outlook remains neutral.…more
$0.1960+1.71%vs prev closeShareBenzinga - 8.11Regular26.08.12 04:02
●●●●●●●● ●●●●● ●●●●●●
테리바 바이오로직스가 전이성 췌장암 환자를 대상으로 한 VCN-01의 임상 2a상 투약을 시작하며 치료 효능 개선을 위한 핵심 데이터를 확보 중이다. 현재 2027년 1분기까지 운영 가능한 현금을 보유하고 있으며, 향후 임상 3상 진입을 위한 용법 최적화에 집중하고 있다.…more
$0.1960+1.71%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report